Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free UPC Stock Alerts

Universe Pharmaceuticals (UPC) Competitors

Universe Pharmaceuticals logo
$2.69 +0.02 (+0.60%)
Closing price 05/14/2026 03:58 PM Eastern
Extended Trading
$2.62 -0.07 (-2.61%)
As of 08:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

UPC vs. TCRT, FBLG, ACXP, CNSP, and CUPR

Should you buy Universe Pharmaceuticals stock or one of its competitors? MarketBeat compares Universe Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Universe Pharmaceuticals include Alaunos Therapeutics (TCRT), FibroBiologics (FBLG), Acurx Pharmaceuticals (ACXP), CNS Pharmaceuticals (CNSP), and Cuprina Holdings (Cayman) (CUPR). These companies are all part of the "pharmaceutical products" industry.

How does Universe Pharmaceuticals compare to Alaunos Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Universe Pharmaceuticals and Universe Pharmaceuticals both had 2 articles in the media. Universe Pharmaceuticals' average media sentiment score of 1.43 beat Alaunos Therapeutics' score of 0.93 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
Alaunos Therapeutics Positive

Universe Pharmaceuticals has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.13, indicating that its stock price is 213% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Universe Pharmaceuticals' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Alaunos Therapeutics N/A -172.65%-123.32%

Universe Pharmaceuticals has higher revenue and earnings than Alaunos Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M0.08-$3.67MN/AN/A
Alaunos TherapeuticsN/AN/A-$4.18M-$2.21N/A

Summary

Universe Pharmaceuticals beats Alaunos Therapeutics on 7 of the 8 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to FibroBiologics?

FibroBiologics (NASDAQ:FBLG) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

FibroBiologics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

In the previous week, FibroBiologics had 3 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 5 mentions for FibroBiologics and 2 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 1.43 beat FibroBiologics' score of 0.47 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
FibroBiologics Neutral
Universe Pharmaceuticals Positive

0.2% of Universe Pharmaceuticals shares are held by institutional investors. 9.3% of FibroBiologics shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Universe Pharmaceuticals' return on equity of 0.00% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
FibroBiologicsN/A -767.07% -195.56%
Universe Pharmaceuticals N/A N/A N/A

FibroBiologics presently has a consensus price target of $74.00, suggesting a potential upside of 6,751.85%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities research analysts clearly believe FibroBiologics is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroBiologics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Universe Pharmaceuticals has higher revenue and earnings than FibroBiologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroBiologicsN/AN/A-$18.65M-$6.93N/A
Universe Pharmaceuticals$17.86M0.08-$3.67MN/AN/A

Summary

Universe Pharmaceuticals beats FibroBiologics on 8 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Acurx Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 1,497.94%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acurx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Acurx Pharmaceuticals has a beta of -2.09, suggesting that its stock price is 309% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

In the previous week, Acurx Pharmaceuticals had 8 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 10 mentions for Acurx Pharmaceuticals and 2 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 1.43 beat Acurx Pharmaceuticals' score of 0.39 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Acurx Pharmaceuticals Neutral
Universe Pharmaceuticals Positive

Universe Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acurx PharmaceuticalsN/A -153.92% -101.69%
Universe Pharmaceuticals N/A N/A N/A

Universe Pharmaceuticals has higher revenue and earnings than Acurx Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/A
Universe Pharmaceuticals$17.86M0.08-$3.67MN/AN/A

Summary

Universe Pharmaceuticals beats Acurx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to CNS Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 299.20%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Universe Pharmaceuticals has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 2 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 1.43 beat CNS Pharmaceuticals' score of 1.06 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
CNS Pharmaceuticals Positive

Universe Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
CNS Pharmaceuticals N/A -164.56%-130.05%

Universe Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M0.08-$3.67MN/AN/A
CNS PharmaceuticalsN/AN/A-$15.85M-$41.30N/A

Summary

Universe Pharmaceuticals and CNS Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Cuprina Holdings (Cayman)?

Universe Pharmaceuticals (NASDAQ:UPC) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cuprina Holdings (Cayman)
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Cuprina Holdings (Cayman) N/A N/A N/A

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 1 mentions for Cuprina Holdings (Cayman). Universe Pharmaceuticals' average media sentiment score of 1.43 beat Cuprina Holdings (Cayman)'s score of 1.28 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
Cuprina Holdings (Cayman) Positive

Cuprina Holdings (Cayman) has lower revenue, but higher earnings than Universe Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M0.08-$3.67MN/AN/A
Cuprina Holdings (Cayman)$40K140.70-$3.63MN/AN/A

Summary

Universe Pharmaceuticals beats Cuprina Holdings (Cayman) on 5 of the 7 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPC vs. The Competition

Export
MetricUniverse PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.50M$3.06B$6.34B$12.37B
Dividend YieldN/A1.96%2.80%5.35%
P/E RatioN/A18.7020.6625.63
Price / Sales0.08271.92542.6376.59
Price / CashN/A57.7843.2656.33
Price / Book0.034.429.936.97
Net Income-$3.67M$72.19M$3.55B$333.62M
7 Day Performance-5.05%-0.43%1.70%1.09%
1 Month Performance-15.93%-0.96%0.49%3.08%
1 Year PerformanceN/A45.81%39.41%35.68%

Universe Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPC
Universe Pharmaceuticals
1.2778 of 5 stars		$2.69
+0.6%		N/AN/A$1.50M$17.86MN/A220
TCRT
Alaunos Therapeutics
1.2539 of 5 stars		$2.63
+1.9%		N/A-12.1%$6.20MN/AN/A40
FBLG
FibroBiologics
3.6452 of 5 stars		$0.99
-14.7%		$74.00
+7,374.7%		-93.5%$6.04MN/AN/A10
ACXP
Acurx Pharmaceuticals
2.0124 of 5 stars		$2.18
+4.3%		$31.00
+1,322.0%		-73.6%$5.97MN/AN/A3
CNSP
CNS Pharmaceuticals
3.5685 of 5 stars		$6.76
-7.3%		$20.00
+195.9%		-63.7%$5.92MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel